Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures -- Ignore unavailable to you. Want to Upgrade?

To: chalu2 who wrote (4)	4/10/1999 8:33:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 226

Don't you wish you had just loaded up on biotech last fall--ImClone from $7 to $17 since then--and a good part of the breakout recently, presumably because data well be presented at the ASCO meeting next Month (correct me if I am wrong). Kurt von Emster may have some of this in FBDIX, although it was not in the top ten holdings of the fund a year ago from what I can tell, but he mentioned it in a recent marketwatch article. I bought that fund for my new Roth IRA a year ago at around $24, which is where it is now I think:-( Uh oh, I am getting off topic! ImClone is a McCamant pick, or at least it has been touted by him recently. I don't own IMCL--I guess I wish I did. Feel free 'chalu2' to summarize the focus of the company for this thread if you would like to.